Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronjon Chakraverty

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood|July 19, 2017
Gene therapy for Wiskott-Aldrich syndrome in a severely affected adultEmma C Morris, Thomas Fox, Ronjon Chakraverty, et al.
The Journal of Clinical Investigation|February 28, 2018
Redirection to the bone marrow improves T cell persistence and antitumor functionsAnjum B Khan, Ben Carpenter, Pedro Santos E Sousa, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|October 2, 2020
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|August 8, 2025
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to ProgressDonal P McLornan, Mette D Hazenberg, Fabio Ciceri, et al.
Blood|September 27, 2022
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunityMorgane Cheminant, Thomas A Fox, Mickael Alligon, et al.
Nature Medicine|April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine|February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood|July 19, 2017
Gene therapy for Wiskott-Aldrich syndrome in a severely affected adultEmma C Morris, Thomas Fox, Ronjon Chakraverty, et al.
The Journal of Clinical Investigation|February 28, 2018
Redirection to the bone marrow improves T cell persistence and antitumor functionsAnjum B Khan, Ben Carpenter, Pedro Santos E Sousa, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|October 2, 2020
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|August 8, 2025
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to ProgressDonal P McLornan, Mette D Hazenberg, Fabio Ciceri, et al.
Blood|September 27, 2022
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunityMorgane Cheminant, Thomas A Fox, Mickael Alligon, et al.
Nature Medicine|April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine|February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Pageof 8